DexCom Inc. closed 50.22% short of its 52-week high of $142.00, which the company achieved on March 26th.

Piper Sandler analyst Matthew O’Brien maintained a Buy rating on Dexcom (DXCM – Research Report) today and set a price target of $100.00. The company’s shares closed last Friday at $77.84.

BofA keeps a Buy rating on DexCom (DXCM) with a $105 price target after Dexcom announced it received a warning letter from the FDA. Importantly, there is no expected impact to the timing of 15-day ...

DexCom projects 2025 revenue of $4.6 billion, representing 14% growth. This forecast assumes strong demand for CGM systems, expanded reimbursement coverage, and a second-half launch of a 15-day G7 ...

My name is Abby, and I will be your conference operator today. At this time, I would like to welcome everyone to the Dexcom Inc. fourth quarter 2024 earnings release conference call. All lines ...

DexCom DXCM-3.22%decrease; red down pointing triangle received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is ...

On Thursday, Dexcom, Inc.'s (NASDAQ:DXCM) fourth-quarter revenue rose 8% year-over-year to $1.114 billion, beating the analyst consensus estimate of $1.104 billion. U.S. revenue rose by 4% ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Friday, shares of DexCom Inc (Symbol: DXCM) entered into oversold territory, hitting an RSI reading of 29.6 ...

DexCom received a warning letter from the Food and Drug Administration following inspections of its San Diego and Mesa, Ariz. facilities and is working on a written response. The diabetes devices ...

The warning letter identified issues in manufacturing processes and quality management system at Dexcom's facilities in San Diego, California and Mesa, Arizona. The company did not provide details ...

Management believes organic revenue is a meaningful metric to investors as it provides a more consistent comparison of Dexcom’s revenue to prior periods as well as to industry peers. We exclude ...